On August 1, 2022, the Company committed to and commenced a restructuring to reduce operating costs and better align its workforce with the needs of its business following the discontinuation of clinical development of NUV-422.
Under the restructuring plan, the Company reduced its workforce by 30 employees (approximately 35%).

Following is a summary of accrued restructuring costs for the three and nine months ended September 30, 2022.


	September 30, 2022
	(In thousands)
Severance and benefit costs	$	1,741
Contract termination costs		5,656
Total restructuring costs		7,397
Cash payments		(4,245	)
Balance at September 30, 2022	$	3,152

Restructuring costs of $0.1 million and $7.3 million were recorded in general and administrative expense and research and development expense, respectively, in our statements of operations and comprehensive loss in the three months ended September 30, 2022. The Company expects that substantially all of the accrued restructuring costs as of September 30, 2022 will be paid in cash by the end of 2022.